Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Assets (2016 - 2025)

Historic Assets for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to $648.4 million.

  • Celldex Therapeutics' Assets fell 2122.75% to $648.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $648.4 million, marking a year-over-year decrease of 2122.75%. This contributed to the annual value of $792.3 million for FY2024, which is 7016.62% up from last year.
  • Per Celldex Therapeutics' latest filing, its Assets stood at $648.4 million for Q3 2025, which was down 2122.75% from $692.4 million recorded in Q2 2025.
  • Over the past 5 years, Celldex Therapeutics' Assets peaked at $868.8 million during Q1 2024, and registered a low of $204.6 million during Q2 2021.
  • Its 5-year average for Assets is $508.3 million, with a median of $444.7 million in 2021.
  • Per our database at Business Quant, Celldex Therapeutics' Assets crashed by 2572.21% in 2023 and then skyrocketed by 19372.4% in 2024.
  • Quarter analysis of 5 years shows Celldex Therapeutics' Assets stood at $444.7 million in 2021, then fell by 20.67% to $352.7 million in 2022, then soared by 32.0% to $465.6 million in 2023, then skyrocketed by 70.17% to $792.3 million in 2024, then fell by 18.16% to $648.4 million in 2025.
  • Its last three reported values are $648.4 million in Q3 2025, $692.4 million for Q2 2025, and $739.5 million during Q1 2025.